FDA Logo links to FDA home page
U.S. Food and Drug Administration
 HHS Logo links to Department of Health and Human Services website

FDA Home Page | Dockets Home Page | Dockets Contacts and Location | Operating Status

horizonal rule

Dockets Management
Dockets Entered On August 7, 2007
Docket # Title
2006N-0454 Use of Ozone-Depleting Substances; Removal of Essential-Use Designations
2006P-0125 Determine whether Dexedrine (dextroamphetamine sulfate) Oral Solution 5 mg/ 5 mL has been voluntarily withdrawn from sale for safety or efficacy reasons
2007D-0125 Guidance for Industry: Evidence-Based Review System for the Scientific Evaluation of Health Claims
2007N-0311 Midodrine Exclusivity Issues
2006N-0454 Use of Ozone-Depleting Substances; Removal of Essential-Use Designations
C 216 H. Robinson Vol #: 3
C 217 D. Potter Vol #: 3
C 218 M. Fiegle Vol #: 3
C 219 J. Allison Vol #: 3
C 220 B. Chambers Vol #: 3
C 221 A. Ledtje Vol #: 3
C 222 A. Terzyk Vol #: 3
C 223 E. Avers Vol #: 3
C 224 J. Metcalf Vol #: 3
C 225 J. Bliss Vol #: 3
C 226 R. Bliss Vol #: 3
C 227 D. Mayconich Vol #: 3
C 228 L. Tarvin Vol #: 3
C 229 G. Weinhold Vol #: 3
C 230 J. Fleharty Vol #: 3
C 231 N. Young Vol #: 3
C 232 F. Leavutt Vol #: 3
C 233 D. Liller Vol #: 3
C 234 L. Dumont Vol #: 3
C 235 J. James Vol #: 3
C 236 E. Leonard Vol #: 3
C 237 P. Rogol Vol #: 3
C 238 L. Isaacs Vol #: 3
C 239 G. Morris Vol #: 3
C 240 A. Hall Vol #: 3
C 241 R. Hisey Vol #: 3
C 242 K. Hisey Vol #: 3
C 243 M. Andronaco Vol #: 3
C 244 W. Bedwell Vol #: 3
C 245 A. Gorrin Vol #: 3
C 246 M. Wilson Vol #: 3
C 247 W. Short Vol #: 3
C 248 J. Savan Vol #: 3
C 249 C. Hartman Vol #: 3
C 250 M. Horn Vol #: 3
C 251 M Iagulli Vol #: 3
C 252 J. Hockenberry Vol #: 3
C 253 H. Schellenbach Vol #: 3
C 254 H Bohan Vol #: 3
C 255 C. Shiplet Vol #: 3
C 256 P. Doughan Vol #: 3
C 257 R. Hinnaman Vol #: 3
C 258 R. Gwilliams Vol #: 3
C 259 R. Feathers Vol #: 3
C 260 O. Hudson Vol #: 3
C 261 N. Wenger Vol #: 3
C 262 E. Shoeman Vol #: 3
C 263 D. Walker Vol #: 3
C 264 J. Divin Vol #: 3
C 265 B. Wioto Vol #: 3
C 266 C. Arthur Vol #: 3
C 267 J. James Vol #: 3
C 268 H. Spackman Vol #: 3
C 269 A. Allan Vol #: 3
C 270 A. Taylor Vol #: 3
C 271 D Osani Vol #: 3
C 272 E. Bosch Vol #: 3
C 273 M. DeCusatis Vol #: 3
C 274 G. Chukinas Vol #: 3
C 275 R. Evans Vol #: 3
C 276 W. Boatwright Vol #: 3
C 277 N. Jimenez Vol #: 3
C 278 M. Yaroch Vol #: 3
C 279 B. Smith Vol #: 3
C 280 H. Zeck Vol #: 3
C 281 C. Meadows Vol #: 3
C 282 B. Cadman Vol #: 3
C 283 Y. Grudzien Vol #: 3
C 284 C. Pederson Vol #: 3
C 285 S. Johnson Vol #: 3
C 286 T. Quinlan Vol #: 3
C 287 M. Wright Vol #: 3
C 288 L. Robinson Vol #: 3
C 289 W. Zimmer Vol #: 3
C 290 L Jones Vol #: 3
C 291 M. Koorndyk Vol #: 3
C 292 J. Brown Vol #: 3
C 293 W. O'Brien Vol #: 3
C 294 D. Robbins Vol #: 3
C 295 L. Talbott Vol #: 3
C 296 D. Lawrence Vol #: 3
C 297 L. Pelletier Vol #: 3
C 298 W. Thomas Vol #: 3
C 299 E. Thompson Vol #: 3
C 300 O. Benson Vol #: 3
C 301 D. Wilson Vol #: 3
C 302 L. Barber Vol #: 3
C 303 G. Myers Vol #: 3
C 304 A. Pitman Vol #: 3
C 305 G Phillips Vol #: 3
C 306 A. Froetschel Vol #: 3
C 307 S. Klikmann Vol #: 3
C 308 N. Saunders Vol #: 3
C 309 W. Jones Vol #: 3
C 310 P. Qualls Vol #: 3
C 311 M. West Vol #: 3
C 312 E. Ryals Vol #: 3
C 313 L. Dobbins Vol #: 3
C 314 S. Uldaneta Vol #: 3
C 315 M. Naylor Vol #: 3
C 316 P. Blackerby Vol #: 3
C 317 S. Blue Vol #: 3
C 318 E. Little Vol #: 3
C 319 R. Crawford Vol #: 3
C 320 J Klug Vol #: 3
C 321 K Rousseau Vol #: 3
C 322 R. Martinson Vol #: 3
C 323 B. Enochs Vol #: 3
C 324 E. Hollwedel Vol #: 3
C 325 J Senko Vol #: 3
C 326 L Goodstein Vol #: 3
C 327 W. Abernethy Vol #: 3
C 328 S. Houchin Vol #: 3
C 329 L. Shcill Vol #: 3
C 330 O. Kinder Vol #: 3
C 331 B Vild Vol #: 3
C 332 J. Porter Vol #: 3
C 333 M. Rushing Vol #: 3
C 334 B. McDonald Vol #: 3
C 335 G. Burner Vol #: 3
C 336 M. Wilcheck Vol #: 3
C 337 R. Mann Vol #: 3
C 338 A. Hostetter Vol #: 3
C 339 M. Florence Vol #: 3
C 340 E. Gonzalez Vol #: 3
C 341 J Squires Vol #: 3
C 342 F. Faulls Vol #: 3
C 343 C. Murdock Vol #: 3
C 344 S. Bonghi Vol #: 3
NEC 1 FDA Vol #: 7
2006P-0125 Determine whether Dexedrine (dextroamphetamine sulfate) Oral Solution 5 mg/ 5 mL has been voluntarily withdrawn from sale for safety or efficacy reasons
N 1 FDA Vol #: 1
2007D-0125 Guidance for Industry: Evidence-Based Review System for the Scientific Evaluation of Health Claims
EMC 1 J. Portelance Vol #: 1
EMC 2 L. Dack Vol #: 1
EMC 3 T. Nelson Vol #: 1
EMC 4 M. Capron Vol #: 1
EMC 5 M. Frances Vol #: 1
EMC 6 E. Kikuchi Vol #: 1
EMC 7 Form Letter Count 6187 Vol #: 2
EMC 8 A. Hall Vol #: 1
EMC 9 L. Carter Vol #: 1
EMC 10 J. Radcliffe Vol #: 1
EMC 11 L. Hustead Vol #: 1
EMC 12 A. Heyes Vol #: 1
EMC 13 D. Bettridge Vol #: 1
EMC 14 E. Whooley Vol #: 1
EMC 15 S. Wasilik Vol #: 1
EMC 16 S. Wasserbach Vol #: 1
EMC 17 M. Esposito Vol #: 1
EMC 18 N. Pitcher Vol #: 1
EMC 19 C. Teasdale Vol #: 1
EMC 20 T. Mariner Vol #: 1
EMC 21 P. Harris Vol #: 1
EMC 22 B. Moseley Vol #: 1
EMC 23 R. Benton Vol #: 1
EMC 24 L. Marsh Vol #: 1
EMC 25 C. Guk Vol #: 1
EMC 26 M. Volansky Vol #: 1
EMC 27 S. Carter Vol #: 1
EMC 28 B. Competiello Vol #: 1
EMC 29 M. Lanciano Vol #: 1
EMC 30 K. Richardson Vol #: 1
EMC 31 A. Maynard Vol #: 1
EMC 32 C. Burrows Vol #: 1
EMC 33 J. Levin Vol #: 1
EMC 34 N. Gay Vol #: 1
EMC 35 B. Hansen-Smith Vol #: 1
EMC 36 B. Anderson Vol #: 1
EMC 37 K. Kirchdoerfer Vol #: 1
EMC 38 D. Yates Vol #: 1
EMC 39 D. Varner-Sheaves Vol #: 1
EMC 40 H. Andrasko Vol #: 1
EMC 41 A. Cappa Vol #: 1
EMC 42 S. Westerdahl Vol #: 1
EMC 43 D. Lambert Vol #: 1
EMC 44 A. Troeh Vol #: 1
EMC 45 N. Ugarte Vol #: 1
EMC 46 E. Sesma Vol #: 1
EMC 47 F. Duckworth Vol #: 1
EMC 48 S. Empie Vol #: 1
EMC 49 E. Armstrong Vol #: 1
EMC 50 M. Nolastname Vol #: 1
EMC 51 J. Christian Vol #: 1
EMC 52 R. Bauer Vol #: 1
EMC 53 M. Foshay Vol #: 1
EMC 54 R. Hoskins Vol #: 1
EMC 55 L. Combs Vol #: 1
2007N-0311 Midodrine Exclusivity Issues
LET 1 FDA/CDER/OGD Vol #: 1

Page created on August 8, 2007 ue

horizonal rule

Dockets Home| Dockets Contacts and Location | Operating Status | Item Code Definitions | Federal Register
FDA Home Page | Search FDA Site | A-Z Index | Contact FDA | Privacy | Accessibility

FDA/Dockets Management